Hear from Allison Moore, Founder/CEO of the Hereditary Neuropathy Foundation about the past, present and future or CMT research.
SORD: A Lesson in Repurposing Drugs to Treat Hereditary Neuropathy
Research from a mutation on the SORD gene
Hear from Allison Moore, Founder/CEO of the Hereditary Neuropathy Foundation about the past, present and future or CMT research.
Research from a mutation on the SORD gene
Community connected with the TRPV4 HN team at Johns Hopkins
The PREMIER Trial, which is being conducted in patients with mild-to-moderate CMT1A, is expected to enroll approximately 350 subjects ages 16-65 with a confirmed genetic diagnosis of CMT1A.
Research with the Department of Cellular and Integrative Physiology UT Health San Antonio, TX
A new type of Charcot-Marie-Tooth (CMT) has recently been identified caused by mutations in the SORD gene.
What GRIN is and why you should join
Participating during CMT month
The FDA has agreed with the key elements of Pharnext’s approach for the developmental pathway to approval for PXT3003.
Alana Kohler’s story of having CMT4A.
US Food and Drug Administration has agreed with Pharnext and provided clear guidance on the regulatory pathway to approval for PXT3003, including key design elements of a single pivotal Phase III study
0 Comments